KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand whom to position…
Treatment of chronic spontaneous and chronic inducible urticaria is dominated by oral medications—both approved (e.g., first- and second-generation antihistamines) and off-label (e.g., DMARDs,…
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand whom to position…
The urticaria drug market is dominated by oral medications, including steroids and second-generation, nondrowsy antihistamines, prescribed for both chronic inducible and chronic spontaneous…
Approximately 80% of rare diseases have a genetic etiology. Gene therapies hold the potential to transform the treatment of rare diseases and may provide a functional cure for some patients…
Systemic lupus erythematosus (SLE) is a complex autoimmune disease that can affect nearly any organ or system in the body. As a result, its course, manifestations, and treatment approach can be…
Copy/Paste the key inputs from the product brochure, per guidance from Marketing. The urticaria drug market is dominated by oral medications, including steroids and second-generation, nondrowsy…
The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 600 currently available and novel biosimilar products, detailing…
Over the past two decades, in response to mounting failures, clinical trials of disease-modifying therapies (DMTs) in Alzheimer’s disease (AD) have moved earlier in the disease spectrum to…
Drug treatment of chronic heart failure (CHF) with reduced ejection fraction (HFrEF) is well established with a wealth of supporting evidence from clinical trials. ACE inhibitors or ARBs, beta-…
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a rare, alloimmune thrombocytopenic disorder affecting fetuses / neonates, characterized in severe cases by intracranial hemorrhage. It can…
Atopic Dermatitis | Emerging Therapies | Eucrisa | US is a three-wave series that tracks the introduction of Pfizer’s Eucrisa for the treatment of AD. The series is based on primary research data…
Pulmonary hypertension (PH) constitutes a group of rare diseases, including pulmonary arterial hypertension (PAH), yet the commercial potential for novel drugs approved for PH indications is…
The chronic obstructive pulmonary disease market is becoming increasingly crowded, and market access in the EU5 is a growing concern as manufacturers attempt to achieve favorable reimbursement…
The Alzheimer’s disease (AD) market comprises a handful of symptomatic treatment options that offer modest efficacy for a limited duration, leaving clear opportunity for more-effective…